Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Do glucocorticoids decrease mortality in acute respiratory distress syndrome? A meta-analysis.

Ritesh Agarwal1, Alok Nath, Ashutosh N Aggarwal

  • 1Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Sector-12, Chandigarh, India. ritesh@indiachest.org

Respirology (Carlton, Vic.)
|June 26, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Indian Council of Medical Research's network of pulmonary fibrosis (INPF): A big step forward towards understanding interstitial lung diseases in India.

Lung India : official organ of Indian Chest Society·2026
Same author

Prevalence of relapse in pulmonary sarcoidosis: A systematic review and meta-analysis.

Respiratory medicine·2026
Same author

Safety and major adverse events of endobronchial ultrasound performed under conscious sedation: Insights from 3,454 procedures over 14 years and a systematic review of literature.

Lung India : official organ of Indian Chest Society·2026
Same author

Efficacy and safety of daily drug regimens containing high-dose versus standard-dose rifampicin for treating pulmonary tuberculosis: Systematic review and meta-analysis.

Lung India : official organ of Indian Chest Society·2026
Same author

A proof of concept study on the diagnostic utility of in vivo expressed mycobacterial transcripts in tuberculous pleuritis.

Scientific reports·2026
Same author

Development and validation of the Hypersensitivity Pneumonitis South Asian Questionnaire for Exposure (HP-SAQE): a novel, qualitative and quantitative tool.

Thorax·2026
Same journal

High-Flow Nasal Oxygen in Early Home Pulmonary Rehabilitation for Exertional Hypoxaemia: A Pilot Randomised Feasibility Trial.

Respirology (Carlton, Vic.)·2026
Same journal

Contemporary Concise Review 2025: Asthma.

Respirology (Carlton, Vic.)·2026
Same journal

Early Intervention With Biologics for Asthma Remission: Promising or Premature?

Respirology (Carlton, Vic.)·2026
Same journal

Clinical and Inflammatory Phenotypes During Exacerbations Predict In-Hospital Adverse Outcomes in Asthma-COPD Overlap.

Respirology (Carlton, Vic.)·2026
Same journal

Diagnostic Yield of EBUS Mediastinal Cryobiopsy Versus TBNA in Suspected Lymphoproliferative Disorders: A Prospective Multicentre Study.

Respirology (Carlton, Vic.)·2026
Same journal

Association of Airway Mucus Plugs and Physical Activity, Exercise Tolerance, Sarcopenia, and Frailty in Patients With COPD and Pre-COPD.

Respirology (Carlton, Vic.)·2026
See all related articles

Corticosteroids do not reduce mortality in acute respiratory distress syndrome (ARDS). Further research is needed for specific patient groups, especially those with severe sepsis and early ARDS or late ARDS.

Area of Science:

  • Critical Care Medicine
  • Pulmonology
  • Pharmacology

Background:

  • Glucocorticoids are known to improve survival in septic shock patients.
  • Acute Respiratory Distress Syndrome (ARDS) is a severe lung condition with high mortality.
  • The role of glucocorticoids in ARDS management remains debated.

Purpose of the Study:

  • To analyze the efficacy of glucocorticoids in reducing mortality in ARDS patients.
  • To investigate the impact of glucocorticoids during both early and fibroproliferative phases of ARDS.

Main Methods:

  • Systematic review of randomized controlled trials and observational studies (1980-2006).
  • Inclusion of studies on ARDS patients treated with glucocorticoids.
  • Calculation of odds ratios and 95% confidence intervals for mortality.

Related Experiment Videos

Main Results:

  • Six trials were included: three in early ARDS (n=300) and three in late ARDS (n=235).
  • Glucocorticoids showed a non-significant odds ratio of 0.57 (95% CI: 0.25-1.32) for early ARDS mortality.
  • Glucocorticoids showed a non-significant odds ratio of 0.58 (95% CI: 0.22-1.53) for late ARDS mortality, with significant heterogeneity observed.

Conclusions:

  • Current evidence does not support the use of corticosteroids for ARDS management in either early or late stages.
  • Further research is necessary to identify specific ARDS subgroups that may benefit from steroid therapy.
  • Subgroups of interest include patients with severe sepsis and early ARDS with relative adrenal insufficiency, and those with late ARDS (7-14 days post-onset).